Announcement on Obtaining Drug Registration Approval
Filed with SSE · · 3 pages · Chinese
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Earlier from Jiangsu Hengrui Pharmaceuticals
- Announcement on Withdrawal of Drug Registration Application
- Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial
- Announcement on Progress in A-share Repurchase
- Announcement on Convening the Q1 2026 Performance Briefing
Later from Jiangsu Hengrui Pharmaceuticals
- Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
- Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces Positive Topline Data from Two Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535
- Announcement on Inclusion of Key Pharmaceutical Products of the Company in the National Essential Medicines List
- Announcement on Inclusion of Drug in Breakthrough Therapy Designation List
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals